XPENG-INC.
29.10.2020 13:02:09 CET | Business Wire | Press release
XPeng Inc. (“XPeng” or the “Company”, NYSE: XPEV), a leading Chinese smart electric vehicle (“Smart EV”) company, this week released its 2nd Smart Car Operations Report, following its 2nd annual Tech Day where the company unveiled its newly developed cutting edge autonomous driving and in-car smart features.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005643/en/
“2020 to 2022 is a period of gaining significant momentum for the Smart EV sector which will rapidly accelerate from 2023 to 2025 and a create massive disruption to traditional ICE vehicles,” said He Xiaopeng, Chairman & CEO of XPeng.
“End-to-end R&D, data-driven capabilities and fast growth are three initiatives needed for a company to gain long-term competitive advantages and dominant market share,” Chairman He added.
At its 2nd Tech Day, XPeng launched 18 firmware OTA updates, adding 82 new features to its vehicles. The voice assistant’s average monthly utilization rate reached 99.74% and in-car navigation utilization rate achieved 92.54%, according to XPeng’s 2020 Smart Car Operations Report.
XPeng’s autonomous driving system XPILOT 3.0, planned for release in the first quarter of 2021, will provide Navigation Guided Pilot (NGP) for highways and memory auto parking for carparks. These new features address some of the major challenges for drivers in China.
Navigation Guided Pilot (NGP)
Built on XPILOT 3.0, the NGP highway solution enables autonomous driving from point A to point B. The solution will be available on all of China’s major highways with high-precision digital maps and will be the most advanced navigation guided autonomous driving system for production models in China.
The NGP system incorporates driving scenarios specific to China such as traffic cone recognition and avoidance, large truck avoidance, night overtaking reminders, faulty vehicle avoidance, and vehicle follow on congested roads. It can also handle adverse weather conditions, complex roads and locations without GPS signals.
The solution will be the only 360° dual-perception system in the industry with optimal identification of automobile surroundings with the most powerful positioning capabilities in production.
Memory Auto Parking
The XPILOT 3.0 will feature a Memory Parking functionality for parking lots. This feature will recognize side-front parking spaces and cover “the last mile” of parking with the ability to avoid obstacles, plan routes and park with extreme precision. The feature is the world's first auto parking system for production vehicles that does not require any car park modifications.
“Our core competitive advantage is our end-to-end in-house developed software for autonomous driving. In the past few years, we have developed a full range of self-developed R&D and implemented these advanced technologies into our models. There are only two auto makers in the world that have end-to-end autonomous driving capabilities and XPeng is one of them,” said XinZhou Wu, Vice President of Autonomous Driving at XPeng.
World’s first All Voice In-car System
XPeng also introduced another update of its Xmart OS operating system with the world’s first All Voice In-car System, able to deliver the majority of in-car functions. The updated system is the world’s first in-car voice system that responds to continuous driver-vehicle dialogues and is able to execute 10 voice commands every 25 seconds.
“Driver-vehicle interaction technology has evolved from physical buttons to touch screens, to today’s voice commands,” said Ji YU, Vice President of Internet at XPeng.
Xmart OS is now the world’s first open-end vehicle hardware system which allows third-party applications to access vehicle status and data to produce tailor-made infotainment. It also has a unique programmable smart lighting system where users can personalize its lighting effects in the future.
Smart Car by Numbers - 2020 Xpeng Operations Report*
XPeng’s 2nd annual Smart Car Operations Report is based on data from XPeng vehicles from Jan 1, 2020 to Sep 30, 2020. The report illustrates the Smart Cars’ most appealing aspects and how customers value smart features.
- Firmware OTA launched - 18 times in the past 20 months
- New features added - 82 items
- Voice assistant monthly average utilization rate - 99.74%
- In-car navigation utilization rate - 92.54%
Intelligence Makes Driving Easier
Driving range
- Longest distance driven by a single vehicle - 3,784 km
- Accumulative monthly mileage driven by all users - 30,300,000 km
Auto Parking
- Average monthly obstacle avoidance - 9,585 times
- Average monthly auto parking - 88,000 times
- Average time taken for auto parking - 32.3 seconds
ACC (Adaptive Cruise Control)
- Utilization rate/month – 65.59%
- Average distance driven/month – 2,286,000 km
- Distance driven/car/day – 24.6 km
LCC (Lane Centering Control)
- Utilization rate/month – 42.48%
- Distance driven/month – 1,127,000 km
- Distance driven/car/day – 21.7 km
Intelligence Makes Interaction Easier
- Voice Assistant “Xiao P” total activation - 17,910,000 times
- Intelligent recommendations provided - 4,484,000 items
- Intelligent navigation routes recommended by voice assistant - 19,170,000 routes
* Data provided by Xpeng Lab based on data from all Xpeng vehicles from 1 January 2020 to 31 September 2020.
About XPeng
XPeng Inc. is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers in China. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack autonomous driving technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrification/electronic architecture. XPeng is headquartered in Guangzhou, China, with offices in Beijing, Shanghai, Silicon Valley, and San Diego. The Company’s Smart EVs are manufactured at plants in Zhaoqing and Zhengzhou, located in Guangdong and Henan provinces, respectively. For more information, please visit https://en.xiaopeng.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005643/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom